Search research articles
Contact Us
Filters
Showing results (141-150 of 251) with videos related to
Page
of 26
Sort By:
Leukemia Research
|
April 1, 2006
A phase II study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients with very high risk relapsed acute myeloid leukemia
Francis Giles, Srdan Verstovsek, Stefan Faderl, et al.
Leukemia Research
|
June 29, 2010
Early introduction of ESA in low risk MDS patients may delay the need for RBC transfusion: a retrospective analysis on 112 patients
Sophie Park, Charikleia Kelaidi, Rosa Sapena, et al.
British Journal of Haematology
|
August 15, 2022
Hepatic haemophagocytosis in haematology patients with hepatic dysfunction: prognostic impact and contribution of liver biopsy combined with the haemophagocytic syndrome diagnostic score (HScore)
Pierre-Nicolas Bris, Philippe Gauchez, Raynier Devillier, et al.
EMBO Molecular Medicine
|
October 11, 2023
Downregulation of stromal syntenin sustains AML development
Raphael Leblanc, Rania Ghossoub, Armelle Goubard, et al.
Frontiers in Immunology
|
May 22, 2018
Immunomodulatory Drugs Exert Anti-Leukemia Effects in Acute Myeloid Leukemia by Direct and Immunostimulatory Activities
Aude Le Roy, Thomas Prébet, Rémy Castellano, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 5, 2012
Outcome of acute promyelocytic leukemia (APL) in children and adolescents: an analysis in two consecutive trials of the European APL Group
Cecile Bally, Jehane Fadlallah, Guy Leverger, et al.
Cell Reports
|
July 14, 2021
BTN2A1, an immune checkpoint targeting Vγ9Vδ2 T cell cytotoxicity against malignant cells
Carla E Cano, Christine Pasero, Aude De Gassart, et al.
Oncotarget
|
November 16, 2017
Outcome of patients treated for myelodysplastic syndromes with 5q deletion after failure of lenalidomide therapy
Thomas Prebet, Thomas Cluzeau, Sophie Park, et al.
Leukemia Research
|
May 30, 2008
Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis and/or at first relapse: results from the GET-LALA group
Oumedaly Reman, Arnaud Pigneux, Françoise Huguet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 21, 2014
International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed/refractory acute myeloid leukemia
Gail J Roboz, Todd Rosenblat, Martha Arellano, et al.
Page
of 26
Search research articles
Search
Showing results (141-150 of 251) with videos related to
Sort By:
Page
of 26
Leukemia Research
|
April 1, 2006
A phase II study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients with very high risk relapsed acute myeloid leukemia
Francis Giles, Srdan Verstovsek, Stefan Faderl, et al.
Leukemia Research
|
June 29, 2010
Early introduction of ESA in low risk MDS patients may delay the need for RBC transfusion: a retrospective analysis on 112 patients
Sophie Park, Charikleia Kelaidi, Rosa Sapena, et al.
British Journal of Haematology
|
August 15, 2022
Hepatic haemophagocytosis in haematology patients with hepatic dysfunction: prognostic impact and contribution of liver biopsy combined with the haemophagocytic syndrome diagnostic score (HScore)
Pierre-Nicolas Bris, Philippe Gauchez, Raynier Devillier, et al.
EMBO Molecular Medicine
|
October 11, 2023
Downregulation of stromal syntenin sustains AML development
Raphael Leblanc, Rania Ghossoub, Armelle Goubard, et al.
Frontiers in Immunology
|
May 22, 2018
Immunomodulatory Drugs Exert Anti-Leukemia Effects in Acute Myeloid Leukemia by Direct and Immunostimulatory Activities
Aude Le Roy, Thomas Prébet, Rémy Castellano, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 5, 2012
Outcome of acute promyelocytic leukemia (APL) in children and adolescents: an analysis in two consecutive trials of the European APL Group
Cecile Bally, Jehane Fadlallah, Guy Leverger, et al.
Cell Reports
|
July 14, 2021
BTN2A1, an immune checkpoint targeting Vγ9Vδ2 T cell cytotoxicity against malignant cells
Carla E Cano, Christine Pasero, Aude De Gassart, et al.
Oncotarget
|
November 16, 2017
Outcome of patients treated for myelodysplastic syndromes with 5q deletion after failure of lenalidomide therapy
Thomas Prebet, Thomas Cluzeau, Sophie Park, et al.
Leukemia Research
|
May 30, 2008
Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis and/or at first relapse: results from the GET-LALA group
Oumedaly Reman, Arnaud Pigneux, Françoise Huguet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 21, 2014
International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed/refractory acute myeloid leukemia
Gail J Roboz, Todd Rosenblat, Martha Arellano, et al.
Page
of 26